TheraCryf PLC
TCF
Company Profile
Business description
TheraCryf PLC is a clinical-stage biotechnology company focused on profitable segments in oncology and neuropsychiatry. The company's lead clinical asset, SFX-01 is a patented form of delivering sulforaphane, which could be used in the treatment of a number of cancers, neurodevelopmental disorders, and other diseases.
Contact
Congleton Road
Alderley Park
Nether AlderleyCheshireSK10 4TG
GBRT: +44 1625315090
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 March 2025
Employees
9
Stocks News & Analysis
stocks
Best and worst performing ASX sectors of 2024
Exploring the ASX sectors that moved the market this year.
stocks
2 ASX companies with the traits of a long-term winner
Two companies that show promising signs of handsomely rewarding shareholders.
video
Our outlook for 2025
Morningstar Equity Market Strategist Lochlan Halloway discusses his view on what we can expect in markets in 2025.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,465.00 | 44.50 | 0.53% |
| CAC 40 | 7,393.76 | 13.02 | 0.18% |
| DAX 40 | 20,024.66 | 115.52 | 0.58% |
| Dow JONES (US) | 42,417.35 | 126.87 | -0.30% |
| FTSE 100 | 8,260.09 | 87.07 | 1.07% |
| HKSE | 19,623.32 | 436.63 | -2.18% |
| NASDAQ | 19,264.97 | 45.83 | -0.24% |
| Nikkei 225 | 39,894.54 | 386.62 | -0.96% |
| NZX 50 Index | 13,110.74 | 159.27 | -1.20% |
| S&P 500 | 5,867.45 | 14.18 | -0.24% |
| S&P/ASX 200 | 8,201.20 | 42.10 | 0.52% |
| SSE Composite Index | 3,262.56 | 89.20 | -2.66% |